N
Nivalis Therapeutics
Developing a novel class of disease modifying therapies for patients with cystic fibrosis
About Nivalis Therapeutics
Nivalis Therapeutics, founded in 2007 and formerly known as N30 Pharmaceuticals, was a clinical-stage pharmaceutical company headquartered in Boulder, Colorado. The company focused on developing small-molecule therapeutics for patients with cystic fibrosis (CF). Nivalis' core strategy revolved around the inhibition of S-nitrosoglutathione reductase (GSNOR), an enzyme linked to depleted levels of S-nitrosoglutathione (GSNO) which is associated with cystic fibrosis.
The company's lead product candidate was cavosonstat (N91115), an orally bioavailable GSNOR inhibitor designed to work as a CFTR modulator. Cavosonstat's mechanism aimed to stabilize the cystic fibrosis transmembrane conductance regulator (CFTR) protein, complementing existing corrector and potentiator therapies. Nivalis advanced cavosonstat through several clinical trials, including Phase 1 studies and multiple Phase 2 trials to evaluate its safety and efficacy as an add-on therapy for patients with specific CFTR mutations. In 2016, the U.S. FDA granted cavosonstat both Fast Track and Orphan Drug designations.
Despite initial promise, a pivotal Phase 2 trial in late 2016 failed to meet its primary endpoint of demonstrating a benefit in lung function. Following these disappointing results, Nivalis announced in early 2017 that it would discontinue the development of cavosonstat for CF, wind down its research and development activities, and explore strategic alternatives. This led to a significant restructuring, including laying off the majority of its staff. After evaluating numerous proposals, Nivalis entered into a definitive merger agreement with Alpine Immune Sciences in April 2017. The all-stock transaction was structured as a reverse merger, which provided Alpine with Nivalis' Nasdaq listing and remaining capital, creating a combined entity focused on developing protein-based immunotherapies for inflammation and immuno-oncology. The merger was completed in the third quarter of 2017, and the combined company continued under the Alpine Immune Sciences name.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jul 2017 | $0 | — | Alpine Immune Sciences | — |
| IPO✓Exit | Jun 2015 | $0 | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Nivalis Therapeutics is 40 monthly website visits, down 71.4% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Nivalis Therapeutics in the Boulder ecosystem
The Nivalis Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Deerfield
Tiger Global
Other known investors2 additional known investors
Alpine Immune Sciences
Case Western Reserve University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nivalis Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nivalis Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









